38064-02-7

Basic information

• Product Name: Benzenesulfenyl chloride, 2,4-dichloro-
• CAS NO: 38064-02-7
• Molecular Formula: C6H3Cl3S
• Molecular Weight: 213.515
• Mol File: 38064-02-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzenesulfenyl chloride, 2,4-dichloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfenyl chloride, 2,4-dichloro-(38064-02-7)
• EPA Substance Registry System: Benzenesulfenyl chloride, 2,4-dichloro-(38064-02-7)

Safety Data

• Hazardous Substances Data: 38064-02-7(Hazardous Substances Data)

Upstream product

• 1122-41-4 2,4-dichlorobenzenethiol 
• 15433-50-8 1,2-bis(2,4-dichlorophenyl)disulfane 
• 61713-34-6 2,4-dichloro-benzenethiol; sodium salt 
• 16271-33-3 2,4-Dichlorobenzenesulfonyl chloride 

Downstream Products

• 61713-35-7 2,4-Dichlorphenyl-methanthiosulphonat 
• 128529-40-8 N-[(2,4-dicblorophenyl)thio]-2,4,6-triphenylaniline 
• 133872-25-0 N¹,N⁵-bis<(2,4-dichlorophenyl)thio>-2,4-diphenyl-1,3,5-triazapenta-1,3-diene 
• 203051-52-9 N-(5'-Chloro-[1,1';3',1'']terphenyl-2'-yl)-S-(2,4-dichloro-phenyl)-thiohydroxylamine 
• 1027295-83-5 1-[2'-(2,4-Dichloro-phenylsulfanylamino)-[1,1';3',1'']terphenyl-5'-yl]-ethanone 
• 203051-51-8 S-(2,4-Dichloro-phenyl)-N-(5'-nitro-[1,1';3',1'']terphenyl-2'-yl)-thiohydroxylamine 
• 1027910-12-8 1-[4,4''-Dichloro-2'-(2,4-dichloro-phenylsulfanylamino)-[1,1';3',1'']terphenyl-5'-yl]-ethanone 
• 1026393-86-1 2'-(2,4-Dichloro-phenylsulfanylamino)-[1,1';3',1'']terphenyl-5'-carboxylic acid ethyl ester 
• 1026413-38-6 N-[(2,4-dichlorophenyl)thio]-4-acetyl-2,4-di(phenyl-d5)aniline 
• 15433-50-8 1,2-bis(2,4-dichlorophenyl)disulfane 
• 74282-76-1 N,N'-Bis(3,5-di-tert-butylphenyl)-N,N'-bis<(2,4-dichlorophenyl)thio>hydrazine 
• 74282-70-5 N-(2,4-Dichlorophenylthio)-3,5-di-tert-butylphenylaminyl 
• 133872-31-8 C₅₂H₃₂Cl₈N₆S₄ 
• 133872-36-3 C₂₆H₁₆Cl₄N₃S₂ 

Relevant articles and documents

Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes

Fructose-1,6-bisphosphatase (FBPase), as a key rate-limiting enzyme in the gluconeogenesis (GNG) pathway, represents a practical therapeutic strategy for type 2 diabetes (T2D). Our previous work first identified cysteine residue 128 (C128) was an important allosteric site in the structure of FBPase, while pharmacologically targeting C128 attenuated the catalytic ability of FBPase. Herein, ten approved cysteine covalent drugs were selected for exploring FBPase inhibitory activities, and the alcohol deterrent disulfiram displayed superior inhibitory efficacy among those drugs. Based on the structure of lead compound disulfiram, 58 disulfide-derived compounds were designed and synthesized for investigating FBPase inhibitory activities. Optimal compound 3a exhibited significant FBPase inhibition and glucose-lowering efficacy in vitro and in vivo. Furthermore, 3a covalently modified the C128 site, and then regulated the N125–S124–S123 allosteric pathway of FBPase in mechanism. In summary, 3a has the potential to be a novel FBPase inhibitor for T2D therapy.

Antidiabetic pyrrolecarboxylic acids

Certain pyrrolecarboxylic and pyrroleacetic acid derivatives substituted on the pyrrole ring with thioether groups, acyl groups, phenyl, substituted phenyl, phenoxy, substituted phenoxy, benzyl or halo and optionally substituted on the pyrrole nitrogen with alkyl, and the pharmaceutically acceptable salts thereof, are useful in lowering the blood glucose levels of hyperglycemic animals.